Skip to main content

Chimerix, Inc. (CMRX)

NASDAQ: CMRX · Delayed Price · USD
6.20
-0.06 (-0.96%)
After-hours:Sep 20, 2021 4:14 PM EDT
6.26
-0.09 (-1.42%)
At close: Sep 20, 4:00 PM
Market Cap539.06M
Revenue (ttm)4.56M
Net Income (ttm)-138.26M
Shares Out86.23M
EPS (ttm)-1.90
PE Ration/a
Forward PE256.41
Dividendn/a
Ex-Dividend Daten/a
Volume838,367
Open6.20
Previous Close6.35
Day's Range6.05 - 6.35
52-Week Range2.43 - 11.57
Beta1.59
AnalystsBuy
Price Target17.67 (+182.3%)
Est. Earnings DateNov 4, 2021

About CMRX

Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 ...

IndustryBiotechnology
IPO DateApr 11, 2013
CEOMichael Sherman
Employees54
Stock ExchangeNASDAQ
Ticker SymbolCMRX
Full Company Profile

Financial Performance

In 2020, Chimerix's revenue was $5.37 million, a decrease of -57.09% compared to the previous year's $12.52 million. Losses were -$43.52 million, -61.34% less than in 2019.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for Chimerix stock is "Buy." The 12-month stock price forecast is 17.67, which is an increase of 182.27% from the latest price.

Price Target
$17.67
(182.27% upside)
Analyst Consensus: Buy

News

Chimerix to Present at H.C. Wainwright 23rd Annual Global Investment Conference

DURHAM, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...

1 week ago - GlobeNewsWire

Chimerix to Present at 2021 Wedbush PacGrow Healthcare Conference

DURHAM, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today...

1 month ago - GlobeNewsWire

Chimerix to Report Second Quarter 2021 Financial Results and Provide an Operational Update on August 5, 2021

DURHAM, N.C., July 29, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today...

1 month ago - GlobeNewsWire

Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox

– First smallpox antiviral approved for all age groups, including infants, and patients who have difficulty swallowing – – First smallpox antiviral approved for all age groups, including infants, and pa...

3 months ago - GlobeNewsWire

Chimerix Announces Upcoming Presentations at the American Society of Clinical Oncology 2021 Annual Meeting

DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today ...

4 months ago - GlobeNewsWire

Chimerix Reports First Quarter 2021 Financial Results and Provides Operational Update

– BCV PDUFA Date Set for July 7 and ONC201 Blinded Independent Central Review Expected in Second Half of 2021 –

4 months ago - GlobeNewsWire

Chimerix (CMRX) Sees Hammer Chart Pattern: Time to Buy?

Chimerix (CMRX) has been struggling lately, but the selling pressure may be coming to an end soon

4 months ago - Zacks Investment Research

Chimerix to Report First Quarter 2021 Financial Results and Provide an Operational Update on May 6, 2021

DURHAM, N.C., April 29, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...

4 months ago - GlobeNewsWire

Chimerix Appoints Vicki Vakiener to Board of Directors

DURHAM, N.C., April 26, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...

4 months ago - GlobeNewsWire

Chimerix Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021

DURHAM, N.C., April 08, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...

5 months ago - GlobeNewsWire

5 Small-Cap Biotech Stocks Trading Under $10 With Massive Upside Potential

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other symbols:AFMDEPZMSEELWVE
5 months ago - 24/7 Wall Street

Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences Conference

DURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...

6 months ago - GlobeNewsWire

Chimerix, Exclusive Worldwide Licensee of Cantex's Investigational Product, DSTAT, Has Announced Promising Topline Re...

WESTON, Fla., Feb. 26, 2021 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of inflammatory lung disease...

6 months ago - PRNewsWire

Chimerix's DSTAT Shows Promising Results In First Cohort Of COVID-19 Study

Chimerix Inc (NASDAQ: CMRX) reports topline results from the first cohort (n=12) of its Phase 2/3 study evaluating DSTAT in hospitalized patients with Acute Lung Injury (ALI) and COVID-19 infection. The...

6 months ago - Benzinga

Steven Cohen Dives Into Chimerix

Billionaire investor Steven Cohen (Trades, Portfolio), who leads Point72 Asset Management, disclosed a 5.37% stake in Chimerix Inc. (NASDAQ:CMRX) earlier this week.

6 months ago - GuruFocus

Chimerix Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

DURHAM, N.C., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases...

7 months ago - GlobeNewsWire

Chimerix Announces Pricing of Public Offering of Common Stock

DURHAM, N.C., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases...

7 months ago - GlobeNewsWire

Chimerix Announces Proposed $75,000,000 Public Offering of Common Stock

DURHAM, N.C., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases...

8 months ago - GlobeNewsWire

Why Chimerix Stock Skyrocketed on Friday

A new acquisition could be quite the shot in the arm for the company.

8 months ago - The Motley Fool

Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program

ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma

8 months ago - GlobeNewsWire

Chimerx's (CMRX) NDA for Brincidofovir Accepted by FDA

Chimerix's (CMRX) NDA for brincidofovir as a medical countermeasure for smallpox has been accepted by the FDA.

9 months ago - Zacks Investment Research

Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox

FDA Grants Priority Review and Sets PDUFA Date for April 7, 2021 FDA Grants Priority Review and Sets PDUFA Date for April 7, 2021

9 months ago - GlobeNewsWire

Chimerix, Inc. (CMRX) CEO Michael Sherman on Q3 2020 Results - Earnings Call Transcript

Chimerix, Inc. (CMRX) CEO Michael Sherman on Q3 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Chimerix to Present at Credit Suisse 29th Annual Healthcare Conference

DURHAM, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today...

10 months ago - GlobeNewsWire

Chimerix to Report Third Quarter 2020 Financial Results and Provide an Operational Update on November 5, 2020

DURHAM, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today...

10 months ago - GlobeNewsWire